Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sonrotoclax combinations versus venetoclax + rituximab in relapsed/refractory CLL/SLL
2024-517131-52-00Phase 3Authorised
- Sponsor
- BeOne Medicines
- Start
- Nov 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 21
01
Overview
Phase 3, randomised, open-label trial in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) comparing BGB-11417 + obinutuzumab, BGB-11417 + rituximab and venetoclax + rituximab (3 arms). Primary endpoint: Progression-free survival. Planned start Nov 2025; status: authorised.
02
Drugs
sonrotoclaxobinutuzumabrituximabvenetoclax
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2024-517131-52-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517131-52-00.